Clinical and serologic features of the study population.
| Feature (Categorical) | OR | 95% CI | p |
|---|---|---|---|
| History of disease activity | |||
| Lupus nephritis | 1.17 | 0.89–1.53 | 0.345 |
| Hematological activity | 1.01 | 0.48–2.06 | 0.597 |
| CNS activity | 2.66 | 1.15–6.17 | 0.025 |
| Disease activity at time of infection | |||
| Lupus nephritis | 1.15 | 0.62–2.13 | 0.41 |
| Hematological activity | 2.11 | 1.07–4.14 | 0.038 |
| CNS activity | 1.01 | 0.89–1.11 | 0.484 |
| Other variables prior to infection | |||
| Immunosuppressive treatment (12 mos) | 1.14 | 0.95–1.36 | 0.229 |
| Positive anti-dsDNA, U/ml | 1.03 | 0.41–2.58 | 0.542 |
| Low C3 levels, mg/dl | 2.71 | 1.25–5.9 | 0.008 |
| Lymphopenia, < 1000/ml | 1.17 | 0.81–1.63 | 0.519 |
| Antibiotic use | 2.18 | 1.43–3.32 | < 0.001 |
| Hospitalization | 2.9 | 1.61–5.2 | < 0.001 |
| Hemodialysis | 1.66 | 0.81–3.4 | 0.231 |
| Other variables at time of the infection | |||
| Immunosuppressive treatment | 1.24 | 1.02–1.05 | 0.039 |
| Prednisone dose | |||
| 0 mg/day | 0.32 | 0.09–0.54 | 0.607 |
| < 7.5 mg/day | 1.12 | 0.98–2.32 | 0.072 |
| 7.5–30 mg/day | 2.22 | 1.50–3.92 | 0.02 |
| > 30 mg/day | 7.14 | 2.69–18.99 | 0.001 |
| Positive anti-dsDNA, U/ml | 1.12 | 0.63–1.4 | 0.506 |
| Low C3 levels, mg/dl | 1.92 | 0.93–3.96 | 0.098 |
| Lymphopenia, < 1000/ml | 1.09 | 0.80–1.23 | 0.604 |
| Nosocomial-acquired infection | 2.77 | 1.46–5.2 | 0.001 |
Values highlighted in bold represent statistically significant p values. CNS: central nervous system.